leadf
logo-loader
viewRevive Therapeutics

Revive Therapeutics signs supply agreement with Havn Life Sciences to source psychedelic compounds for use in future studies

Revive, which has developed a psilocybin oral-thin film product, is planning a Phase 1 clinical study using the naturally derived drug to treat methamphetamine use disorder

Revive Therapeutics - Revive Therapeutics Ltd signs supply agreement with Havn Life Sciences Inc to source naturally derived psychedelic compounds such as psilocybin for use in future studies
Havn Life is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) has signed a supply agreement with Havn Life Sciences Inc. (CSE:HAVN) (FRA:5NP) to source naturally derived psychedelic compounds such as psilocybin for use in future investigational new drug (IND) enabling studies and clinical trials under US Food and Drug Administration guidelines. 

"We are excited about our strategic partnership with Havn Life as one of our suppliers of psychoactive compounds that we intend to develop and commercialize using our established tannin-chitosan based proprietary oral-thin film delivery system, for the pharmaceutical and wellness markets,” said Revive CEO Michael Frank in a statement Tuesday. 

“We are developing unique products with both synthetic and naturally-derived psilocybin and building relationships with companies and institutions that support our objectives in the psychedelic space including our established relationship with the University of Wisconsin-Madison in the research and clinical development of our novel Psilocybin oral-thin film product and the Phase 1 clinical study using psilocybin in the treatment of methamphetamine use disorder.”

READ: Revive Therapeutics to start enrolling patients in Phase 3 coronavirus trial of Bucillamine

Ontario-based Revive said that Havn Life is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds.

“Our path at Havn Life has always been very clear: to supply standardized, quality-controlled compounds to researchers so they can do the research that’s necessary to document health and wellness benefits of psychedelic medicine and ultimately help the industry with the knowledge required to legalize these compounds,” said Susan Chapelle, co-CEO of Havn Life.

Under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, Revive is developing its tannin-chitosan composite of orally dissolvable thin films that offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin, allowing the drug to enter the bloodstream rapidly.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Revive Therapeutics

Price: 0.29 CAD

CSE:RVV
Market: CSE
Market Cap: $57.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read